COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,674 Articles (22,913 medRxiv, 8,761 bioRxiv)

Most recent first Previous |  Page 604: Articles 6031-6040  | Next

Evolving SARS-CoV-2 virulence among hospital and university affiliates in Spain and Greater Boston
Amer, F., Lan, F.-Y., Gil-Conesa, M., Sidossis, A., Bruque, D., Iliaki, E., Buley, J., Nathan, N., Bruno-Murtha, L. A., Carlos-Chilleron, S., Kales, S. N., Fernandez-Montero, A.
10.1101/2022.11.28.22282412 — Posted: 2022-11-29
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England
Patel, V., Yarwood, M. J., Levick, B., Gibbons, D. C., Drysdale, M., Kerr, W., Watkins, J. D., Young, S., Pierce, B. F., Lloyd, E. J., Birch, H. J., Kamalati, T., Brett, S. J.
10.1101/2022.11.28.22282808 — Posted: 2022-11-29
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
Andersson, N. W., Thiesson, E. M., Baum, U., Pihlstrom, N., Starrfelt, J., Faksova, K., Poukka, E., Lund, L. C., Hansen, C. H., Aakjaer, M., Andersen, M., Kjaer, J., Cohet, C., Goossens, M., Hallas, J., Meijerink, H., Rickard, L., Hviid, A.
10.1101/2022.11.24.22282651 — Posted: 2022-11-29
Fc-gamma receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2
Mackin, S. R., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., Diamond, M. S.
10.1101/2022.11.27.518117 — Posted: 2022-11-29
Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Adams, L. E., Leist, S. R., Dinnon, K. H., West, A., Gully, K. L., Anderson, E., Loome, J. F., Madden, E., Powers, J., Schaefer, A., Sarkar, S., Castillo, I., Maron, J., McNamara, R. P., Bertera, H. L., Zweigart, M. R., Higgins, J. S., Hampton, B. K., Lakshmanane, P., Alter, G., Montgomery, S., Baxter, V., Heise, M. T., Baric, R. S.
10.1101/2022.11.28.518175 — Posted: 2022-11-28
Extracellular disintegration of viral proteins as an innovative strategy for developing broad-spectrum antivirals against coronavirus
Sun, K., Ding, Z., Jia, X., Cheng, H., Li, Y., Wu, Y., Li, Z., Huang, X., Pu, F., Li, E., Wang, G., Wang, W., Ding, Y., Wong, G., Chiu, S., Lan, J., Hu, A.
10.1101/2022.11.24.517008 — Posted: 2022-11-28
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
Boschi, C., Scheim, D. E., Bancod, A., Millitello, M., Le Bideau, M., Colson, P., Fantini, J., La Scola, B.
10.1101/2022.11.24.517882 — Posted: 2022-11-28
Highly potent antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 RNA genome
Dauksaite, V., Tas, A., Wachowius, F., Spruit, A., van Hemert, M., Snijder, E., van der Veer, E. P., van Zonneveld, A. J.
10.1101/2022.11.28.518195 — Posted: 2022-11-28
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., Wang, H. H., Gordon, A., Liu, L., Ho, D. D.
10.1101/2022.11.23.517532 — Posted: 2022-11-28
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB.
Sullivan, D. J., Franchini, M., Senefeld, J., Joyner, M., Casadevall, A., Focosi, D.
10.1101/2022.11.25.517977 — Posted: 2022-11-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).